FR11C0007I2 - PHARMACEUTICAL COMPOSITION STABILIZED USING A BASIC AGENT - Google Patents
PHARMACEUTICAL COMPOSITION STABILIZED USING A BASIC AGENTInfo
- Publication number
- FR11C0007I2 FR11C0007I2 FR11C0007C FR11C0007C FR11C0007I2 FR 11C0007 I2 FR11C0007 I2 FR 11C0007I2 FR 11C0007 C FR11C0007 C FR 11C0007C FR 11C0007 C FR11C0007 C FR 11C0007C FR 11C0007 I2 FR11C0007 I2 FR 11C0007I2
- Authority
- FR
- France
- Prior art keywords
- pharmaceutical composition
- basic agent
- composition stabilized
- stabilized
- basic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP35465495 | 1995-12-22 | ||
| PCT/JP1996/003722 WO1997023200A1 (en) | 1995-12-22 | 1996-12-20 | Pharmaceutical composition stabilized with a basic agent |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR11C0007I1 FR11C0007I1 (en) | 2011-04-22 |
| FR11C0007I2 true FR11C0007I2 (en) | 2012-03-16 |
Family
ID=18439011
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR11C0007C Active FR11C0007I2 (en) | 1995-12-22 | 2011-03-17 | PHARMACEUTICAL COMPOSITION STABILIZED USING A BASIC AGENT |
Country Status (26)
| Country | Link |
|---|---|
| EP (1) | EP0814782B1 (en) |
| JP (1) | JP3276962B2 (en) |
| KR (1) | KR100348842B1 (en) |
| CN (1) | CN1137684C (en) |
| AT (1) | ATE228354T1 (en) |
| AU (1) | AU725622B2 (en) |
| CA (1) | CA2213608C (en) |
| CZ (1) | CZ288545B6 (en) |
| DE (2) | DE122011000014I1 (en) |
| DK (1) | DK0814782T3 (en) |
| ES (1) | ES2183023T3 (en) |
| FR (1) | FR11C0007I2 (en) |
| HU (1) | HU227798B1 (en) |
| IL (1) | IL121565A (en) |
| MX (1) | MX9706389A (en) |
| NO (2) | NO316724B1 (en) |
| NZ (1) | NZ324446A (en) |
| PL (1) | PL186907B1 (en) |
| PT (1) | PT814782E (en) |
| RU (1) | RU2142790C1 (en) |
| SI (1) | SI0814782T1 (en) |
| SK (1) | SK282991B6 (en) |
| TW (1) | TW436294B (en) |
| UA (1) | UA29513C2 (en) |
| WO (1) | WO1997023200A1 (en) |
| ZA (1) | ZA9610792B (en) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CO5140079A1 (en) * | 1998-10-14 | 2002-03-22 | Novartis Ag | PHARMACEUTICAL COMPOSITION OF SUSTAINED LIBERATION AND METHOD TO RELEASE A PHARMACEUTICALLY ACTIVE AGENT FROM SUSTAINED LIBERATION AND METHOD TO RELEASE A PHARMACEUTICALLY ACTIVE AGENT |
| SI20109A (en) * | 1998-12-16 | 2000-06-30 | LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. | Stable pharmaceutical formulation |
| JP2002538202A (en) * | 1999-03-08 | 2002-11-12 | メルク エンド カムパニー インコーポレーテッド | Dihydroxy open acid of HMG-CoA reductase inhibitor and salt thereof |
| EP1036563A1 (en) * | 1999-03-08 | 2000-09-20 | MERCK & CO. INC. | Delayed-release oral formulation of dihydroxy open acid simvastatin and salts and esters thereof |
| US6569461B1 (en) | 1999-03-08 | 2003-05-27 | Merck & Co., Inc. | Dihydroxy open-acid and salts of HMG-CoA reductase inhibitors |
| JP4048780B2 (en) * | 1999-12-13 | 2008-02-20 | 株式会社豊田中央研究所 | Quinoline derivative compound and organic electroluminescent device |
| GB0001621D0 (en) * | 2000-01-26 | 2000-03-15 | Astrazeneca Ab | Pharmaceutical compositions |
| USRE44578E1 (en) | 2000-04-10 | 2013-11-05 | Teva Pharmaceutical Industries, Ltd. | Stable pharmaceutical compositions containing 7-substituted-3,5-dihydroxyheptanoic acids or 7-substituted-3,5-dihydroxyheptenoic acids |
| US6242003B1 (en) | 2000-04-13 | 2001-06-05 | Novartis Ag | Organic compounds |
| US6806290B2 (en) | 2000-06-09 | 2004-10-19 | Lek Pharmaceuticals D.D. | Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same |
| SK16982002A3 (en) | 2000-06-09 | 2003-04-01 | Lek Pharmaceuticals D. D. | Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same |
| US20060127474A1 (en) | 2001-04-11 | 2006-06-15 | Oskar Kalb | Pharmaceutical compositions comprising fluvastatin |
| TW200404544A (en) * | 2002-06-17 | 2004-04-01 | Kowa Co | Controlled release pharmaceutical composition |
| AU2003264443A1 (en) * | 2002-09-20 | 2004-04-08 | Kowa Co., Ltd. | Preparation for external use |
| AR041089A1 (en) | 2003-05-15 | 2005-05-04 | Merck & Co Inc | PROCEDURE AND PHARMACEUTICAL COMPOSITIONS TO TREAT ATEROSCLEROSIS, DYSLIPIDEMIAS AND RELATED AFFECTIONS |
| WO2005062824A2 (en) | 2003-12-23 | 2005-07-14 | Merck & Co., Inc. | Anti-hypercholesterolemic compounds |
| WO2005063294A1 (en) | 2003-12-30 | 2005-07-14 | Kowa Company, Ltd. | Inhibitor for the formation of ϝ-secretase complex |
| US8314124B2 (en) | 2004-02-06 | 2012-11-20 | Active Biotech Ab | Crystalline salts of quinoline compounds and methods for preparing them |
| SE0400235D0 (en) | 2004-02-06 | 2004-02-06 | Active Biotech Ab | New composition containing quinoline compounds |
| WO2005079846A1 (en) | 2004-02-25 | 2005-09-01 | Kowa Company, Ltd. | NUCLEAR TRANSFER PROMOTER FOR Rac PROTEIN AND METHOD OF SCREENING THE SAME |
| EP1719525B1 (en) | 2004-02-25 | 2014-12-10 | Kowa Company, Ltd. | Nuclear transfer promoter for cdc42 protein and method of screening the same |
| US20060211752A1 (en) | 2004-03-16 | 2006-09-21 | Kohn Leonard D | Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression |
| UA87854C2 (en) | 2004-06-07 | 2009-08-25 | Мерк Энд Ко., Инк. | N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators |
| CN101098700A (en) | 2005-01-06 | 2008-01-02 | 默克公司 | Drug combination therapy and pharmaceutical compositions for treating inflammatory disorders |
| EP1726962A1 (en) * | 2005-05-24 | 2006-11-29 | Leiden University Medical Center | Apolipoprotein E plasma levels for monitoring and reducing the risk of cardiovascular disease |
| CN101103983B (en) * | 2006-07-14 | 2012-09-26 | 海南盛科生命科学研究院 | Medicinal composition stabilized by base reagent containing pitavastatin calcium and preparation technology thereof |
| WO2008156721A1 (en) | 2007-06-20 | 2008-12-24 | Merck & Co., Inc. | Diphenyl substituted alkanes |
| US8372877B2 (en) | 2010-04-16 | 2013-02-12 | Cumberland Pharmaceuticals | Stabilized statin formulations |
| KR20130137623A (en) | 2010-10-06 | 2013-12-17 | 고쿠리츠다이가쿠호우진 도쿄다이가쿠 | Prophylactic and/or therapeutic agent lymphedema |
| CN103384661B (en) | 2011-01-20 | 2016-08-10 | 默沙东公司 | Mineralocorticoid receptor antagonists |
| JP5988963B2 (en) * | 2011-04-12 | 2016-09-07 | 沢井製薬株式会社 | Pitavastatin-containing preparation and method for producing the same |
| US9487506B2 (en) | 2011-04-13 | 2016-11-08 | Merck Sharp & Dohme Corp. | Mineralocorticoid receptor antagonists |
| WO2012153181A1 (en) | 2011-05-11 | 2012-11-15 | Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi | Pharmaceutical composition comprising pitavastatin or its pharmaceutically acceptable salts |
| CN102861018A (en) * | 2011-07-05 | 2013-01-09 | 南京长澳医药科技有限公司 | Pitavastatin calcium preparation and preparation technology |
| JP5809467B2 (en) * | 2011-07-12 | 2015-11-11 | エルメッド エーザイ株式会社 | Pitavastatin-containing composition and method for producing the same |
| JP5844574B2 (en) * | 2011-08-10 | 2016-01-20 | 共和薬品工業株式会社 | Stabilized drug composition containing pitavastatin |
| US9505730B2 (en) | 2011-10-13 | 2016-11-29 | Merck Sharp & Dohme Corp. | Mineralocorticoid receptor antagonists |
| JP5190159B1 (en) | 2012-08-08 | 2013-04-24 | 興和株式会社 | Medicine |
| CN102885797A (en) * | 2012-10-29 | 2013-01-23 | 福州海王福药制药有限公司 | Composition containing pravastatin calcium as well as preparation method and application thereof |
| US9750723B2 (en) | 2013-10-31 | 2017-09-05 | Ohio University | Prevention and treatment of non-alcoholic fatty liver disease |
| RU2016146826A (en) | 2014-05-30 | 2018-07-04 | Пфайзер Инк. | CARBONITRIL DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS |
| US10023567B2 (en) | 2014-07-18 | 2018-07-17 | Ohio University | Imidazole and thiazole compositions for modifying biological signaling |
| CN105343008A (en) * | 2015-12-15 | 2016-02-24 | 青岛华之草医药科技有限公司 | Pitavastatin calcium composition |
| CN107913257A (en) * | 2016-10-10 | 2018-04-17 | 北京阜康仁生物制药科技有限公司 | A kind of pharmaceutical composition comprising rosuvastain calcium and preparation method thereof |
| JP6937195B2 (en) * | 2017-09-01 | 2021-09-22 | 興和株式会社 | Pharmaceutical composition |
| WO2023275715A1 (en) | 2021-06-30 | 2023-01-05 | Pfizer Inc. | Metabolites of selective androgen receptor modulators |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1327010C (en) * | 1986-02-13 | 1994-02-15 | Tadashi Makino | Stabilized solid pharmaceutical composition containing antiulcer benzimidazole compound and its production |
| CA1336714C (en) * | 1987-08-20 | 1995-08-15 | Yoshihiro Fujikawa | Quinoline type mevalonolactone inhibitors of cholesterol biosynthesis |
| US5030447A (en) * | 1988-03-31 | 1991-07-09 | E. R. Squibb & Sons, Inc. | Pharmaceutical compositions having good stability |
| JP3528186B2 (en) * | 1991-06-24 | 2004-05-17 | 日産化学工業株式会社 | Diastereomeric salts of optically active quinoline mevalonic acid |
| HU217629B (en) * | 1991-12-12 | 2000-03-28 | Novartis Ag. | Process for producing stabilized pharmaceutical compositions comprising fluvastatin |
-
1996
- 1996-12-20 SK SK1160-97A patent/SK282991B6/en not_active IP Right Cessation
- 1996-12-20 AT AT96942588T patent/ATE228354T1/en active
- 1996-12-20 JP JP52350097A patent/JP3276962B2/en not_active Expired - Lifetime
- 1996-12-20 KR KR1019970705768A patent/KR100348842B1/en not_active IP Right Cessation
- 1996-12-20 UA UA97084351A patent/UA29513C2/en unknown
- 1996-12-20 EP EP96942588A patent/EP0814782B1/en not_active Expired - Lifetime
- 1996-12-20 CN CNB961920653A patent/CN1137684C/en not_active Expired - Lifetime
- 1996-12-20 ZA ZA9610792A patent/ZA9610792B/en unknown
- 1996-12-20 DE DE201112000014 patent/DE122011000014I1/en active Pending
- 1996-12-20 WO PCT/JP1996/003722 patent/WO1997023200A1/en active IP Right Grant
- 1996-12-20 ES ES96942588T patent/ES2183023T3/en not_active Expired - Lifetime
- 1996-12-20 IL IL12156596A patent/IL121565A/en not_active IP Right Cessation
- 1996-12-20 AU AU11715/97A patent/AU725622B2/en not_active Expired
- 1996-12-20 SI SI9630566T patent/SI0814782T1/en unknown
- 1996-12-20 CZ CZ19972681A patent/CZ288545B6/en not_active IP Right Cessation
- 1996-12-20 PL PL96321868A patent/PL186907B1/en unknown
- 1996-12-20 NZ NZ324446A patent/NZ324446A/en not_active IP Right Cessation
- 1996-12-20 DK DK96942588T patent/DK0814782T3/en active
- 1996-12-20 CA CA002213608A patent/CA2213608C/en not_active Expired - Lifetime
- 1996-12-20 PT PT96942588T patent/PT814782E/en unknown
- 1996-12-20 RU RU97114095A patent/RU2142790C1/en active
- 1996-12-20 DE DE69625046T patent/DE69625046T2/en not_active Expired - Lifetime
- 1996-12-20 HU HU9903536A patent/HU227798B1/en unknown
- 1996-12-21 TW TW085115860A patent/TW436294B/en not_active IP Right Cessation
-
1997
- 1997-08-19 NO NO19973814A patent/NO316724B1/en not_active IP Right Cessation
- 1997-08-21 MX MX9706389A patent/MX9706389A/en unknown
-
2011
- 2011-03-17 FR FR11C0007C patent/FR11C0007I2/en active Active
- 2011-05-04 NO NO2011006C patent/NO2011006I2/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FR11C0007I2 (en) | PHARMACEUTICAL COMPOSITION STABILIZED USING A BASIC AGENT | |
| GR3031304T3 (en) | 6-Dimethylaminomethyl-1-phenyl-cyclo-hexane compounds as pharmaceutical agents | |
| FR2734483B1 (en) | PHARMACEUTICAL ADMINISTRATION FORM COMPRISING OXYBUTYNIN | |
| NO20004345D0 (en) | Pharmaceutical composition | |
| CY2005007I2 (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING DARIFENACINE | |
| FI973243A (en) | A new pharmaceutical combination | |
| DZ2494A1 (en) | Pharmaceutical composition of omeprazole. | |
| IS4706A (en) | pharmaceutical compositions | |
| ZA965368B (en) | A pharmaceutical formulation | |
| IT1313549B1 (en) | HEPOTYLONE-BASED PHARMACEUTICAL FORMULATIONS 3 | |
| AP9100340A0 (en) | Pharmaceutical agents | |
| MA26507A1 (en) | AEROSOL PHARMACEUTICAL COMPOSITIONS | |
| FI955311A (en) | Pharmaceutical composition base | |
| ZA96124B (en) | A pharmaceutical formulation | |
| FR2751540B1 (en) | ANTITHROMBOTIC PHARMACEUTICAL COMPOSITION | |
| BR9610214A (en) | Pharmaceutical compounds | |
| EE9900545A (en) | A pharmaceutical composition | |
| IL112639A0 (en) | A pharmaceutical composition containing pravastin | |
| DE69614407D1 (en) | PHARMACEUTICAL COMPOSITIONS | |
| FR2732217B1 (en) | SOLID ADMINISTRATION FORM FOR ORAL USE | |
| MA26531A1 (en) | PHARMACEUTICAL COMPOSITION | |
| FR2768447B1 (en) | Gantry for limiting the height of a passage | |
| ZA964372B (en) | A pharmaceutical formulation | |
| ITMI913510A1 (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING HIGH-BIOAVAILABILITY PROGESTERONE | |
| ZA965367B (en) | A pharmaceutical formulation |